Avastin, Jevtana And Faslodex Among Stada’s 2021 Complex Offerings
Stada Enjoys 8% Top Line Growth In 2021 But Adjusted EBITDA Dips By 1%
Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.
You may also be interested in...
Stada has announced the appointment of former Sandoz executive Christine Berndt as head of global development for specialty and biosimilar products, replacing Michael Mack.
Stada strengthened its position as Europe's fourth-largest OTC player in 2021 as sales at its Consumer Healthcare business jumped by 15%.
Stada says it is taking action to address current disruptions to the supply of tamoxifen in Germany, with the firm’s Aliud Pharma subsidiary bringing in supplies from Stada’s EG business in Italy.